Epigenetic regulation in the carcinogenesis of cholangiocarcinoma

International Journal of Biochemistry and Cell Biology

Volumn 67, Issue , 2015, Pages 110-114

  Chiang, Nai Jung ^a,b,c   Shan, Yan Shen ^a,c   Hung, Wen Chun ^b   Chen, Li Tzong ^b,c,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cholangiocarcinoma; DNA methylation; Epigenetic regulation; Histone modification; microRNA

Indexed keywords

MICRORNA; CELL CYCLE PROTEIN; HISTONE;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; DNA MODIFICATION; DNA REPAIR; EPIGENETICS; HISTONE MODIFICATION; HUMAN; HUMAN CELL; METASTASIS; PROMOTER REGION; BILE DUCT TUMOR; CELL CYCLE; DNA METHYLATION; EPITHELIUM CELL; GENETIC EPIGENESIS; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOGENESIS; CELL CYCLE; CELL CYCLE PROTEINS; CHOLANGIOCARCINOMA; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; HISTONES; HUMANS; MICRORNAS; PROMOTER REGIONS, GENETIC;

EID: 84940898286     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2015.06.012     Document Type: Review

References (50)

1. J.B. Andersen, B. Spee, B.R. Blechacz, I. Avital, M. Komuta, A. Barbour, and et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 142 2012 1021 e5 1031 e5
2. C. Ang Role of the fibroblast growth factor receptor axis in cholangiocarcinoma J. Gastroenterol. Hepatol. 30 2015 1116 1122
3. B.G. Bitler, K.M. Aird, A. Garipov, H. Li, M. Amatangelo, A.V. Kossenkov, and et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers Nat. Med. 21 2015 231 238
4. W. Chan-On, M.L. Nairismagi, C.K. Ong, W.K. Lim, S. Dima, C. Pairojkul, and et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers Nat. Genet. 45 2013 1474 1478 10.038/ng.2806 Epub 013 Nov 3
5. J.S. Chen, C. Hsu, N.J. Chiang, C.S. Tsai, H.H. Tsou, S.F. Huang, and et al. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer Ann. Oncol. 26 2015 943 949
6. P. Chinnasri, C. Pairojkul, P. Jearanaikoon, B. Sripa, V. Bhudhisawasdi, S. Tantimavanich, and et al. Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma Hum. Pathol. 40 2009 817 826
7. P.B. Dallas, I.W. Cheney, D.W. Liao, V. Bowrin, W. Byam, S. Pacchione, and et al. p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes Mol. Cell. Biol. 18 1998 3596 3603
8. P.B. Dallas, S. Pacchione, D. Wilsker, V. Bowrin, R. Kobayashi, and E. Moran The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity Mol. Cell. Biol. 20 2000 3137 3146
9. A. Dey, D. Seshasayee, R. Noubade, D.M. French, J. Liu, M.S. Chaurushiya, and et al. Loss of the tumor suppressor BAP1 causes myeloid transformation Science 337 2012 1541 1546
10. S. Foja, M. Goldberg, U. Schagdarsurengin, R. Dammann, A. Tannapfel, and W.G. Ballhausen Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas Liver Int. 25 2005 1202 1208
11. A. Fujimoto, Y. Totoki, T. Abe, K.A. Boroevich, F. Hosoda, H.H. Nguyen, and et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators Nat. Genet. 44 2012 760 764
12. B. Goeppert, C. Konermann, C.R. Schmidt, O. Bogatyrova, L. Geiselhart, C. Ernst, and et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway Hepatology 59 2014 544 554 10.1002/hep.26721 Epub 2013 Dec 24
13. N. Guo, R. Chen, Z. Li, Y. Liu, D. Cheng, Q. Zhou, and et al. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells Acta Biochim. Biophys. Sin. (Shanghai) 43 2011 354 361 10.1093/abbs/gmr021 Epub 2011 Mar 29
14. H. Haga, I. Yan, K. Takahashi, J. Wood, and T. Patel Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma Gene Expr. 16 2014 93 99 10.3727/105221614X13919976902174
15. Q. Huang, L. Liu, C.H. Liu, H. You, F. Shao, F. Xie, and et al. MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis Asian Pac. J. Cancer Prev. 14 2013 829 834
16. H. Isomoto Epigenetic alterations associated with cholangiocarcinoma (review) Oncol. Rep. 22 2009 227 232
17. D.E. Jensen, M. Proctor, S.T. Marquis, H.P. Gardner, S.I. Ha, L.A. Chodosh, and et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression Oncogene 16 1998 1097 1112
18. Y. Jiao, T.M. Pawlik, R.A. Anders, F.M. Selaru, M.M. Streppel, D.J. Lucas, and et al. Exome sequencing identifies frequent inactivating mutations in BAP1. ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Nat. Genet. 45 2013 1470 1473 10.038/ng.2813 Epub 013 Nov 3
19. J. Lee, D.H. Kim, S. Lee, Q.H. Yang, D.K. Lee, S.K. Lee, and et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4 Proc. Natl. Acad. Sci. U.S.A. 106 2009 8513 8518
20. S. Lee, W.H. Kim, H.Y. Jung, M.H. Yang, and G.H. Kang Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma Am. J. Pathol. 161 2002 1015 1022
21. L. Li, D. Masica, M. Ishida, C. Tomuleasa, S. Umegaki, A.N. Kalloo, and et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis Hepatology 60 2014 896 907
22. T. Limpaiboon, P. Khaenam, P. Chinnasri, M. Soonklang, P. Jearanaikoon, B. Sripa, and et al. Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma Cancer Lett. 217 2005 213 219
23. X.F. Liu, S.G. Zhu, H. Zhang, Z. Xu, H.L. Su, S.J. Li, and et al. The methylation status of the TMS1/ASC gene in cholangiocarcinoma and its clinical significance Hepatobiliary Pancreat. Dis. Int. 5 2006 449 453
24. L. Lu, K. Byrnes, C. Han, Y. Wang, and T. Wu miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth Mol. Cancer Res. 12 2014 890 900
25. B. Luo, H.W. Cheung, A. Subramanian, T. Sharifnia, M. Okamoto, X. Yang, and et al. Highly parallel identification of essential genes in cancer cells Proc. Natl. Acad. Sci. U.S.A. 105 2008 20380 20385
26. M. Miwa, S. Honjo, G. You, M. Tanaka, K. Uchida, P. Srivatanakul, and et al. Genetic and environmental determinants of risk for cholangiocarcinoma in Thailand World J. Gastrointest. Pathophysiol. 5 2014 570 578
27. S. Nakagawa, H. Okabe, Y. Sakamoto, H. Hayashi, D. Hashimoto, N. Yokoyama, and et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis Ann. Surg. Oncol. 20 2013 S667 S675 10.1245/s10434-013-3135-y Epub 2013 Jul 26
28. S. Nakagawa, Y. Sakamoto, H. Okabe, H. Hayashi, D. Hashimoto, N. Yokoyama, and et al. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells Oncol. Rep. 31 2014 983 988 10.3892/or.2013.922 Epub Dec 13
29. M.R. O'Dell, J.L. Huang, C.L. Whitney-Miller, V. Deshpande, P. Rothberg, V. Grose, and et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma Cancer Res. 72 2012 1557 1567
30. K. Okamoto, K. Miyoshi, and Y. Murawaki miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells PLoS One 8 2013 e77623 10.1371/journal.pone.0077623 eCollection 2013
31. C.K. Ong, C. Subimerb, C. Pairojkul, S. Wongkham, I. Cutcutache, W. Yu, and et al. Exome sequencing of liver fluke-associated cholangiocarcinoma Nat. Genet. 44 2012 690 693 10.1038/ng.2273
32. K. Piontek, and F.M. Selaru MicroRNAs in the biology and diagnosis of cholangiocarcinoma Semin. Liver Dis. 35 2015 55 62 10.1055/s-0034-1397349 Epub 2015 Jan 29
33. S.K. Saha, C.A. Parachoniak, K.S. Ghanta, J. Fitamant, K.N. Ross, M.S. Najem, and et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer Nature 513 2014 110 114
34. D.S. Sandhu, A.M. Shire, and L.R. Roberts Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets Liver Int. 28 2008 12 27
35. J.C. Scheuermann, A.G. de Ayala Alonso, K. Oktaba, N. Ly-Hartig, R.K. McGinty, S. Fraterman, and et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB Nature 465 2010 243 247
36. K. Shannon, and M. Hermiston A(nother) RAF mutation in LCH Blood 123 2014 3063 3065
37. D. Sia, B. Losic, A. Moeini, L. Cabellos, K. Hao, K. Revill, and et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma Nat. Commun. 6 2015 6087 10.1038/ncomms7087
38. D.J. Smiraglia, L.J. Rush, M.C. Fruhwald, Z. Dai, W.A. Held, J.F. Costello, and et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies Hum. Mol. Genet. 10 2001 1413 1419
39. M.R. Stratton, P.J. Campbell, and P.A. Futreal The cancer genome Nature 458 2009 719 724
40. A. Tannapfel, F. Sommerer, M. Benicke, L. Weinans, A. Katalinic, F. Geissler, and et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma J. Pathol. 197 2002 624 631
41. I. Tischoff, A. Markwarth, H. Witzigmann, D. Uhlmann, J. Hauss, A. Mirmohammadsadegh, and et al. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors Int. J. Cancer 115 2005 684 689
42. M. Toyota, H. Suzuki, T. Yamashita, K. Hirata, K. Imai, T. Tokino, and et al. Cancer epigenomics: implications of DNA methylation in personalized cancer therapy Cancer Sci. 100 2009 787 791 10.1111/j.349-7006.2009.01095.x Epub 2009 Feb 19
43. T. Tozawa, G. Tamura, T. Honda, S. Nawata, W. Kimura, N. Makino, and et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients Cancer Sci. 95 2004 736 740
44. J. Valle, H. Wasan, D.H. Palmer, D. Cunningham, A. Anthoney, A. Maraveyas, and et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N. Engl. J. Med. 362 2010 1273 1281 10.056/NEJMoa0908721
45. L. Xiaofang, T. Kun, Y. Shaoping, W. Zaiqiu, and S. Hailong Correlation between promoter methylation of p14(ARF). TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma World J. Surg. Oncol. 10 2012 5
46. B. Yang, M.G. House, M. Guo, J.G. Herman, and D.P. Clark Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma Mod. Pathol. 18 2005 412 420
47. L. Yao, C. Han, K. Song, J. Zhang, K. Lim, and T. Wu omega-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression Cancer Res. 75 2015 1388 1398
48. Z.J. Zang, I. Cutcutache, S.L. Poon, S.L. Zhang, J.R. McPherson, J. Tao, and et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes Nat. Genet. 44 2012 570 574
49. H. Zhu, C. Han, D. Lu, and T. Wu miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator Am. J. Pathol. 184 2014 2828 2839
50. S. Zou, J. Li, H. Zhou, C. Frech, X. Jiang, J.S. Chu, and et al. Mutational landscape of intrahepatic cholangiocarcinoma Nat. Commun. 5 2014 5696 10.1038/ncomms6696